Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itzchak Angel

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
British Journal of Clinical Pharmacology|June 21, 2005
Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humansGilad Rosenberg, Itzchak Angel, Alex Kozak
Current Opinion in Drug Discovery & Development|March 13, 2003
Bioactive lipids and their receptorsItzchak Angel, Adina Bar, Rachel Haring
Journal of Diabetes and Its Complications|April 23, 2013
Combating diabetes complications by 1-Fe, a corrole-based catalytic antioxidantAdi Haber, Itzchak Angel, Atif Mahammed, et al.
Biochemistry|September 7, 2005
Membrane interactions and metal ion effects on bilayer permeation of the lipophilic ion modulator DP-109Sofiya Kolusheva, Jonathan Friedman, Itzchak Angel, et al.
Frontiers in Pharmacology|September 18, 2025
Oral administration of Ketamir-2, a novel ketamine analog, attenuates neuropathic pain in rodent models via selective NMDA antagonismItzchak Angel, Rita Perelroizen, Eddy Pichinuk, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 11, 2026
Telomir-Zn restores glucose homeostasis and reduces insulin resistance in a diet-induced zebrafish model of type 2 diabetesItzchak Angel, Kalaichitra Periyasamy, Benin Joseph, et al.
International Journal of Molecular Sciences|May 27, 2026
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of ObesityItzchak Angel, Kalaichitra Periyasamy, Benin Joseph, et al.
Frontiers in Pharmacology|July 8, 2025
KETAMIR-2, a new molecular entity and novel ketamine analogItzchak Angel, Rita Perelroizen, Wendy Deffains, et al.
Neurobiology of Aging|October 7, 2004
The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic miceJoo-Yong Lee, Jonathan E Friedman, Itzchak Angel, et al.
Plos One|November 21, 2012
I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagilineYaron D Barac, Orit Bar-Am, Esti Liani, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
British Journal of Clinical Pharmacology|June 21, 2005
Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humansGilad Rosenberg, Itzchak Angel, Alex Kozak
Current Opinion in Drug Discovery & Development|March 13, 2003
Bioactive lipids and their receptorsItzchak Angel, Adina Bar, Rachel Haring
Journal of Diabetes and Its Complications|April 23, 2013
Combating diabetes complications by 1-Fe, a corrole-based catalytic antioxidantAdi Haber, Itzchak Angel, Atif Mahammed, et al.
Biochemistry|September 7, 2005
Membrane interactions and metal ion effects on bilayer permeation of the lipophilic ion modulator DP-109Sofiya Kolusheva, Jonathan Friedman, Itzchak Angel, et al.
Frontiers in Pharmacology|September 18, 2025
Oral administration of Ketamir-2, a novel ketamine analog, attenuates neuropathic pain in rodent models via selective NMDA antagonismItzchak Angel, Rita Perelroizen, Eddy Pichinuk, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 11, 2026
Telomir-Zn restores glucose homeostasis and reduces insulin resistance in a diet-induced zebrafish model of type 2 diabetesItzchak Angel, Kalaichitra Periyasamy, Benin Joseph, et al.
International Journal of Molecular Sciences|May 27, 2026
SKNY-1, a THCV Analog, Produces Weight Loss, Lipid Normalization and Attenuation of Reward-Associated Behaviors in an mc4r(G894C) Zebrafish Model of ObesityItzchak Angel, Kalaichitra Periyasamy, Benin Joseph, et al.
Frontiers in Pharmacology|July 8, 2025
KETAMIR-2, a new molecular entity and novel ketamine analogItzchak Angel, Rita Perelroizen, Wendy Deffains, et al.
Neurobiology of Aging|October 7, 2004
The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic miceJoo-Yong Lee, Jonathan E Friedman, Itzchak Angel, et al.
Plos One|November 21, 2012
I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagilineYaron D Barac, Orit Bar-Am, Esti Liani, et al.
Pageof 2